Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Commentary

Incidence and Risk Factors of Venous and Arterial Thromboembolism in Immune Checkpoint Inhibitor Therapy

Author(s): Tingting Liu* and Liang V. Tang*

Volume 28, Issue 36, 2022

Published on: 04 October, 2022

Page: [2950 - 2952] Pages: 3

DOI: 10.2174/1381612828666220919123712

conference banner
« Previous Next »
[1]
Moik F, Chan W-S Evelyn, Wiedemann S, et al. Incidence, risk factors and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood 2020; 137(12): 1669-78.
[http://dx.doi.org/10.1182/blood.2020007878]
[2]
Kewan T, Ko T, Flores M, Sallam Y, Haddad A, Daw H. Prognostic impact and risk factors of cancer‐associated thrombosis events in stage‐IV cancer patients treated with immune checkpoint inhibitors. Eur J Haematol 2021; 106(5): 682-8.
[http://dx.doi.org/10.1111/ejh.13598]
[3]
Sussman TA, Li H, Hobbs B, Funchain P, McCrae KR, Khorana AA. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival. J Immunother Cancer 2021; 9(1): e001719.
[http://dx.doi.org/10.1136/jitc-2020-001719]
[4]
Giustozzi M, Becattini C, Roila F, Agnelli G, Mandal M. Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis. Cancer Treat Rev 2021; 100: 102280.
[http://dx.doi.org/10.1016/j.ctrv.2021.102280]
[5]
Campia U. Vascular effects of cancer treatments. Vasc Med 2020; 25(3): 226-34.
[http://dx.doi.org/10.1177/1358863X20914978] [PMID: 32539632]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy